- Conditions
- Hemophilia A, Hemophilia B
- Interventions
- fitusiran, factor concentrates
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 12 Years and older · Male only
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 8
- States / cities
- Little Rock, Arkansas • Gainesville, Florida • Tampa, Florida + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–12
of 12
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Hemophilia A, Immune Tolerance
- Interventions
- FVIII, Emicizumab
- Drug
- Lead sponsor
- Children's Hospital Los Angeles
- Other
- Eligibility
- 0 Years to 12 Years · Male only
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Hemophilia
- Interventions
- Fitusiran, Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate (ATIIIC)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 12 Years and older · Male only
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 8
- States / cities
- Orange, California • Minneapolis, Minnesota • Hackensack, New Jersey + 5 more
- Conditions
- Hemophilia A
- Interventions
- Fitusiran (SAR439774), Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate (ATIIIC), Emicizumab
- Drug · Biological
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 12 Years and older · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Von Willebrand Disease, Type 3
- Interventions
- Von Willebrand Factor Concentrates, Von Willebrand Factor Concentrates and Factor VIII Concentrates, Factor VIII Concentrates, Recombinant Activated Factor VII, Activated Prothrombin Complex Concentrate
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 3
- States / cities
- Sacramento, California • Minneapolis, Minnesota • St Louis, Missouri
- Conditions
- Severe Hemophilia A
- Interventions
- VWF/FVIII concentrates
- Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- Male only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2020
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Hemophilia
- Interventions
- Fitusiran, Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate (ATIIIC)
- Drug · Biological
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 1 Year to 11 Years · Male only
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Orange, California • Las Vegas, Nevada + 2 more
- Conditions
- Hemophilia A With Inhibitors
- Interventions
- Factor VIII concentrates, Low-dose treatment, High-dose treatment
- Drug · Other
- Lead sponsor
- New York Presbyterian Hospital
- Other
- Eligibility
- Up to 7 Years
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2012
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Duarte, California • Orange, California + 31 more
- Conditions
- Haemophilia A
- Interventions
- Not listed
- Lead sponsor
- Octapharma
- Industry
- Eligibility
- Not listed
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2030
- U.S. locations
- 5
- States / cities
- Miami, Florida • New Orleans, Louisiana • St Louis, Missouri + 2 more
- Conditions
- Hemophilia A
- Interventions
- FVIII immuno-assay
- Other
- Lead sponsor
- Children's Hospital Los Angeles
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Burlington, Vermont
- Conditions
- Hemophilia A
- Interventions
- PLASMA DERIVED Factor VIII, Recombinant FVIII
- Drug
- Lead sponsor
- Fondazione Angelo Bianchi Bonomi
- Other
- Eligibility
- 1 Minute to 6 Years · Male only
- Enrollment
- 303 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 10
- States / cities
- Duarte, California • Los Angeles, California • Aurora, Colorado + 7 more
- Conditions
- Von Willebrand Disease, Type 3
- Interventions
- Emicizumab, von Willebrand Factor (VWF) Concentrates, Factor VIII (FVIII) Concentrates, von Willebrand Factor (VWF) and Factor VIII (FVIII) Concentrates, Bypassing Agents
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 1 Month and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 5
- States / cities
- Sacramento, California • Gainesville, Florida • Minneapolis, Minnesota + 2 more